187 related articles for article (PubMed ID: 35953818)
1. Ryanodine receptor 1-mediated Ca
Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
3. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
4. Reduced threshold for store overload-induced Ca
Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
[TBL] [Abstract][Full Text] [Related]
5. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract][Full Text] [Related]
6. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
9. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.
Zhao F; Li P; Chen SR; Louis CF; Fruen BR
J Biol Chem; 2001 Apr; 276(17):13810-6. PubMed ID: 11278295
[TBL] [Abstract][Full Text] [Related]
10. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
[TBL] [Abstract][Full Text] [Related]
11. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.
Hu W; Zhang L; Ferri-Borgogno S; Kwan SY; Lewis KE; Cun HT; Yeung TL; Soliman PT; Tarapore RS; Allen JE; Guan X; Lu KH; Mok SC; Au-Yeung CL
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867127
[TBL] [Abstract][Full Text] [Related]
12. An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities.
Lopez RJ; Byrne S; Vukcevic M; Sekulic-Jablanovic M; Xu L; Brink M; Alamelu J; Voermans N; Snoeck M; Clement E; Muntoni F; Zhou H; Radunovic A; Mohammed S; Wraige E; Zorzato F; Treves S; Jungbluth H
Sci Signal; 2016 Jul; 9(435):ra68. PubMed ID: 27382027
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Yadav G; Roque DM; Bellone S; Manavella DD; Hartwich TMP; Zipponi M; Harold J; Tymon-Rosario J; Mutlu L; Altwerger G; Menderes G; Ratner E; Buza N; Hui P; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Aug; 166(2):351-357. PubMed ID: 35641325
[TBL] [Abstract][Full Text] [Related]
14. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
18. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y; Zarrella DT; Pooladanda V; Azimi Mohammadabadi M; Kim E; Kumar S; Xu M; Qin X; Ray LJ; Devins KM; Kumar R; Kononenko A; Eisenhauer E; Veillard IE; Yamagami W; Hill SJ; Sarosiek KA; Yeku OO; Spriggs DR; Rueda BR
Br J Cancer; 2024 May; 130(9):1463-1476. PubMed ID: 38438589
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.
Lopez-Mejia IC; Pijuan J; Navaridas R; Santacana M; Gatius S; Velasco A; Castellà G; Panosa A; Cabiscol E; Pinyol M; Coll L; Bonifaci N; Peña LP; Vidal A; Villanueva A; Gari E; Llobet-Navàs D; Fajas L; Matias-Guiu X; Yeramian A
Mol Oncol; 2023 Jan; 17(1):98-118. PubMed ID: 36409196
[TBL] [Abstract][Full Text] [Related]
20. Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.
Gomez AC; Holford TW; Yamaguchi N
Am J Physiol Cell Physiol; 2016 Nov; 311(5):C749-C757. PubMed ID: 27558158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
